ALPHA-ADRENOCEPTOR VASCULAR FUNCTION IN CHRONIC KIDNEY DISEASE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是更多地了解为什么大多数早期肾病患者都有高血压。 我们知道，人体会产生天然物质，当需要时，这些物质会导致血管张开得更大，从而输送更多的血液。一个例子是在锻炼期间。其他天然物质会导致血管变小，并在需要时减缓血液流动。一个例子是当人们很冷的时候。这些物质之间的平衡很重要。患有肾脏疾病和高血压的人没有这些物质的正常平衡。 这项研究将包括3组人，血压正常者、高血压者和肾病患者。 “受试者将接受筛查身体检查，包括心电图和实验室检查。 高血压患者在住院GCRC检查前的3周内不能服用常规降压药。 在住院研究期间，受试者将接受动脉内药物治疗，这些药物将导致血管发生变化。 然后，研究将比较这三组人的反应。将进行GFR测试，以确认慢性肾脏疾病组的肾功能。 这些研究将为进展性肾脏疾病患者血管反应性增强的发病机制提供深入的认识。这将为在迅速增长的CKD患者群体中治疗和预防血管疾病的新战略奠定基础。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to learn more about why most patients with early stages of kidney disease have high blood pressure. We know the body produces natural substances that cause blood vessels to open wider to carry more blood when needed. An example is during exercise. Other natural substances cause blood vessels to get smaller and slow down blood flow when needed. An example is when people are cold. The balance between these substances is important. People with kidney disease and high blood pressure do not have the normal balance of these substances. This study will include 3 groups of people, people with normal blood pressure, people with high blood pressure and people with kidney disease. " Subjects will have a screening physical examination, including an ECG and laboratory tests " Subjects with high blood pressure may not take their regular blood pressure medication for 3 weeks prior to the inpatient GCRC study " Subjects will be given intra-arterial medications that will cause changes in the blood vessels during the in-patient study. The study will then compare the responses of the three groups. A GFR test will be done to confirm the renal function of the group with chronic kidney disease. These studies will provide insight into the mechanisms of the pathogenesis of enhanced ¿1 vasoreactivity in subjects with progressive renal disease. This will lay the groundwork for new strategies in the treatment and prevention of vascular disease among the rapidly growing group of individuals with CKD.'